GlassScriptPhysician profile
Sonia Deora
NPI 1235134297
$10,328.45
in general payments reported to CMS, 2019-2025
42 companies · $1,569 in 2025
The $1,569 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,835 · 2020: $1,039 · 2021: $1,509 · 2022: $1,604 · 2023: $1,292 · 2024: $1,481 · 2025: $1,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,342.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,204.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,048.13 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Novo Nordisk INC | $1,032.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $922.69 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.94 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $467.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $452.49 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $327.52 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Amgen INC. | $258.00 | 2021-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $159.17 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $151.21 | 2019-2021 | |
| Abbott Laboratories | $135.80 | 2021-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $128.07 | 2019-2025 | |
| Dexcom, INC. | $100.74 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $82.99 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Deora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.